Toshifumi Yokota

8613-114 St
Edmonton, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 186 publications

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook.

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook.

Journal: RNA biology

Published: June 22, 2026

DMD-Null mice exhibit severe muscle weakness, impaired regeneration, and deficient satellite cell function.

DMD-Null mice exhibit severe muscle weakness, impaired regeneration, and deficient satellite cell function.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 16, 2026

Molecular Diagnosis to Individualized Therapies in Rare Genetic Diseases: New Approach Methodologies, RNA Therapeutics, and the Case for a Human-First Filter.

Molecular Diagnosis to Individualized Therapies in Rare Genetic Diseases: New Approach Methodologies, RNA Therapeutics, and the Case for a Human-First Filter.

Journal: Genes

Published: May 01, 2026

RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies.

RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies.

Journal: Biomolecules

Published: April 26, 2026

Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine: The Next Step in Interventional Genetics.

Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine: The Next Step in Interventional Genetics.

Journal: Genes

Published: April 24, 2026

The Multi-System Roles of Dp71 Dystrophin Isoforms in Duchenne Muscular Dystrophy.

The Multi-System Roles of Dp71 Dystrophin Isoforms in Duchenne Muscular Dystrophy.

Journal: Muscles (Basel, Switzerland)

Published: March 29, 2026

Application of Omics Analysis in the Clinical Practice and Research of Transthyretin Amyloidosis.

Application of Omics Analysis in the Clinical Practice and Research of Transthyretin Amyloidosis.

Journal: Genes

Published: January 29, 2026

From Genomic Diagnosis to Personalized RNA Medicine: Advances in Next-Generation Sequencing and N-of-1 Antisense Oligonucleotide Therapies for Rare Genetic Diseases.

From Genomic Diagnosis to Personalized RNA Medicine: Advances in Next-Generation Sequencing and N-of-1 Antisense Oligonucleotide Therapies for Rare Genetic Diseases.

Journal: Genes

Published: November 15, 2025

DG9-Conjugated Morpholino-Based Exon 51-Skipping Therapy for Duchenne Muscular Dystrophy.

DG9-Conjugated Morpholino-Based Exon 51-Skipping Therapy for Duchenne Muscular Dystrophy.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 01, 2025

DG9-Conjugated Morpholino Rescues Phenotype in Spinal Muscular Atrophy Mice.

DG9-Conjugated Morpholino Rescues Phenotype in Spinal Muscular Atrophy Mice.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 01, 2025

Upgrading nucleic acid and antisense therapeutics: challenges, solutions, and future directions.

Upgrading nucleic acid and antisense therapeutics: challenges, solutions, and future directions.

Journal: Bioanalysis

Published: September 22, 2025

Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders.

Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders.

Journal: Genes

Published: September 17, 2025

Showing 1-12 of 186

Last Updated: 09/26/2026